INmune Bio, Inc. Q3 2025 Earnings Recap

INMB Q3 2025 November 1, 2025

INmune Bio reported significant progress in the third quarter of 2025, highlighted by advancements in its CORDStrom and XPro platforms, alongside an accelerated development pipeline aimed at addressing unmet medical needs.

Earnings Per Share Beat

$-0.24 vs $-0.31 est.

+22.6% surprise

Market Reaction

1-Day +0.0%

5-Day -10.93%

30-Day -9.84%

Key Takeaways

Preparing for regulatory submissions for CORDStrom in the U.K. and U.S. targeting recessive dystrophic epidermolysis bullosa (RDEB).
Positive interim results from the Phase II MINDFuL trial for XPro in Alzheimer's disease, indicating potential efficacy linked to baseline inflammation levels.
Completion of the INKmune Phase II trial in prostate cancer ahead of schedule, with key endpoints met.
A multi-platform strategy demonstrating viability with two late-stage therapeutics advancing in development.
Anticipation of pivotal 2026 milestones, including regulatory discussions and potential market approvals.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit INMB on AllInvestView.